Bionomics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch Bionomics and buy or sell other stocks, ETFs, and their options commission-free!About BNOX
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor.
CEOSpyridon Papapetropoulos, MD, PhD
CEOSpyridon Papapetropoulos, MD, PhD
Employees7
Employees7
HeadquartersBurlington, Massachusetts
HeadquartersBurlington, Massachusetts
Founded
Founded
Employees7
Employees7
BNOX Key Statistics
Market cap36.08M
Market cap36.08M
Price-Earnings ratio-0.81
Price-Earnings ratio-0.81
Dividend yield—
Dividend yield—
Average volume97.62K
Average volume97.62K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$19.66
52 Week high$19.66
52 Week low$2.12
52 Week low$2.12